The treatment of Sjögren's syndrome patients with Pilocarpine-tablets

References

• Sjogren H. Zur Kenntnis der keratoconjunctivitis sicca (kerat-itis filiforms beihypofunktion der tranendrusen). Acta Ophthal 1933; Suppl II: 1–151.
   Google Scholar
• Talal N, Moutsopoulos H, Karsan S, eds. SjOgren's Syndrome: Clinical and Immunologic Aspects. Heidelberg, Germany: Springer-Verlag 1987.
   Google Scholar
• Oxholm P, Prause JU, Schiodt M. Rational drug therapy recommendations for the treatment of patients with Sjogren's syndrome. Drugs 1998;56:345–53.
   Google Scholar
• Linardaki G, Moutsopoulus HM. The uncertain role of immunosuppressive agents in SjOgren's syndrome. Cleve Clin J Med 1997;64:523–6.
   PubMed Web of Science ®Google Scholar
• Shiozawa S, Tanaka Y, Shiozawa K. Single- blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerosto-mia in patients with Sjogren's syndrome. J Interferon Cytokine Res 1998;18:255–62.
   Google Scholar
• Ship JA, Fox PC, Michalek JE et al. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: A phase II clinical trial. J Interferon Cytokine Res 1999;19:943–51.
   PubMed Web of Science ®Google Scholar
• Hadden WB. On dry mouth, or suppression of the salivary and buccal secretions. Trans Clin Soc Lond 1888;20:176–9.
   Google Scholar
• Frost-Larsen K, Isager H, Manthorpe R. SjOgren's syndrome treated with bromhexine: a randomized clinical study. BMJ 1978;1:1579–81.
   Google Scholar
• Manthorpe R, Frost-Larsen K, Hoj L, et al. Bromhexine treatment of Sjogren's syndrome. Effect on lacrimal and saliv-ary secretion and on proteins in tear fluid and saliva. Scand J Rheumatology 1981;10:177–80.
   Google Scholar
• Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xero-stomia. Drugs 1995;49:143–55.
   PubMed Web of Science ®Google Scholar
• Johnson FT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-radiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390–5.
   PubMed Web of Science ®Google Scholar
• LeVeque FG, Montgomery M, Potter D. et al. A multicenter, randomized, double-blind, placebo-controlled dose titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clinical Oncol 1993;11:1124–31.
   Google Scholar
• Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with SjOgren's syndrome. Arch Intern Med 1999;159:174–81.
   PubMed Web of Science ®Google Scholar
• Papas A, Charney M, Goden H. et al. The effectiveness of oral pilocarpine-HC1 tablets for the treatment of dry mouth symptoms associated with SjOgren's syndrome - a dose-titration study. Arthritis Rheum. 1997;40 Suppl 9: S202.
   Google Scholar
• Nelson JD, Friedlaender MH, Yeatts RP. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with SjOgren's syndrome. The MGI Pharma SjOgren's Syndrome Study Group. Adv Exp Med Biol 1998;438:979–83.
   Google Scholar
• Vivino F, Leveque F, Khan Z, et al. Long-term safety of pilocarpine tables following chronic administration to patients with SjOgren's syndrome for the relief of symptoms of dry mouth and dry eyes. (Abstract), Arthritis Rheum 1998;41 Suppl 9:S353.
   Google Scholar
• LeVeque F, Khan Z, Salibury PL et al. Sustained increases in salivary flow and safety findings following extended use of pilocarpine tablets for the treatment of dry mouth symptoms in patients with SjOgren's syndrome. (Abstract), Arthritis Rheum 1999;42 Suppl 9:S139.
   Google Scholar
• Salagen tablets. In: Physicians Desk Reference, 55th ed. Montvale, NJ: Medical Economics Books 2000;1924–6.
   Google Scholar
• Daniels TE, Fox PC. Salivary and oral components of SjOgren's syndrome. Rheum D is Clin North Am 1992;18:571–89.
   PubMed Web of Science ®Google Scholar
• Friendlaender MH. Ocular manifestations of SjOgren's syn-drome: keratoconjunctivitis sicca. Rheum D is Clin North Am 1992;18:591–608.
   PubMed Web of Science ®Google Scholar
• O'Connell AC, Pearson AC, Bowen WH. Pilocarpine alters caries development in partially-desalivated rats. J Dent Res. 1994;73:637–43.
   PubMed Web of Science ®Google Scholar
• Leach SA, Connell R. Reversal of fissure caries in the albino rat by stimulating salivary flow with pilocarpine. Caries Res 1990; 24:127–129.
   PubMed Web of Science ®Google Scholar
• Vivino FB, Orlin SE. SjOgren's syndrome: Giving dry mouth and dry eyes the full treatment. J Musculoskel Med 2000;17:350–67.
   Google Scholar
• Rhodus NL, Liljemark W, Bloomquist BA, et al. Candida albicans levels in patients with SjOgren's syndrome before and after long-term use of pilocarpine hydrochloride: A pilot study. Quintessence Int 1998; 29:705–10.
   PubMed Web of Science ®Google Scholar
• Vivino FB, Hermann GA: Scintigraphic predictors of response to treatment in SjOgren's syndrome. (Abstract), Arthritis Rheum 2000;43 Suppl 9:S408.
   Google Scholar
• Hermann GA, Vivino FB, Shnier D, et al. Variability of quantitative scintigraphic salivary indices in normals; causes and implications for xerostomic patients. J Nucl Med 1998;39:1260–3.
   PubMed Web of Science ®Google Scholar
• Vitali C, Moutsopoulus HM, Bombardieri S. et al. The European Community Study Group on diagnostic criteria for SjOgren's syndrome: sensitivity and specificity of tests for ocular and oral involvement in SjOgren's syndrome. Ann Rheum Dis 1994;53:637–47.
   Google Scholar